Journal article Open Access

Molecular targets for AIDS therapy

Mitsuya, H.; Yarchoan, R.; Broder, S.


DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://zenodo.org/record/1230944</identifier>
  <creators>
    <creator>
      <creatorName>Mitsuya, H.</creatorName>
      <givenName>H.</givenName>
      <familyName>Mitsuya</familyName>
    </creator>
    <creator>
      <creatorName>Yarchoan, R.</creatorName>
      <givenName>R.</givenName>
      <familyName>Yarchoan</familyName>
    </creator>
    <creator>
      <creatorName>Broder, S.</creatorName>
      <givenName>S.</givenName>
      <familyName>Broder</familyName>
    </creator>
  </creators>
  <titles>
    <title>Molecular targets for AIDS therapy</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>1990</publicationYear>
  <dates>
    <date dateType="Issued">1990-09-28</date>
  </dates>
  <resourceType resourceTypeGeneral="JournalArticle"/>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/1230944</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1126/science.1699273</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/publicdomain/zero/1.0/legalcode">Creative Commons Zero v1.0 Universal</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">The development of antiretroviral therapy against acquired immunodeficiency syndrome (AIDS) has been an intense research effort since the discovery of the causative agent, human immunodeficiency virus (HIV). A large array of drugs and biologic substances can inhibit HIV replication in vitro. Nucleoside analogs--particularly those belonging to the dideoxynucleoside family--can inhibit reverse transcriptase after anabolic phosphorylation. 3'-Azido-2',3'-dideoxythymidine (AZT) was the first such drug tested in individuals with AIDS, and considerable knowledge of structure-activity relations has emerged for this class of drugs. However, virtually every step in the replication of HIV could serve as a target for a new therapeutic intervention. In the future, non-nucleoside-type drugs will likely become more important in the experimental therapy of AIDS, and antiretroviral therapy will exert major effects against the morbidity and mortality caused by HIV.</description>
  </descriptions>
</resource>
482
290
views
downloads
Views 482
Downloads 290
Data volume 884.0 MB
Unique views 460
Unique downloads 275

Share

Cite as